A  	A  	 DT	O
CASE  	CASE  	 NN	O
OF  	OF  	 IN	O
ADVANCED  	ADVANCED  	 NNP	B-NP
BLADDER  	BLADDER  	 NNP	I-NP
NEUROENDOCRINE  	NEUROENDOCRINE  	 NNP	I-NP
CARCINOMA  	CARCINOMA  	 NNP	I-NP
( 	( 	 -LRB-	O
SMALL  	SMALL  	 NNP	O
CELL  	CELL  	 NNP	B-NP
CARCINOMA 	CARCINOMA 	 NNP	I-NP
)  	)  	 -RRB-	O
SIGNIFICANTLY  	SIGNIFICANTLY  	 NNP	O
IMPROVED  	IMPROVED  	 NNP	O
BY  	BY  	 NNP	O
LOW  	LOW  	 NNP	O
DOSE  	DOSE  	 NNP	O
OF  	OF  	 IN	O
ORAL  	ORAL  	 NNP	B-NP
TEGAFUR-URACIL  	TEGAFUR-URACIL  	 NNP	I-NP
A  	A  	 NNP	O
81-old-woman  	81-old-woman  	 NNP	O
underwent  	underwent  	 VBD	O
a  	a  	 DT	O
transurethral  	transurethral  	 JJ	B-NP
resection  	resection  	 NN	I-NP
of  	of  	 IN	I-NP
bladder  	bladder  	 JJ	I-NP
tumor  	tumor  	 NN	I-NP
( 	( 	 -LRB-	O
TURBT 	TURBT 	 NNP	B-NP
)  	)  	 -RRB-	O
at  	at  	 IN	O
a  	a  	 DT	O
nearby  	nearby  	 JJ	O
hospital  	hospital  	 NN	O
in  	in  	 IN	O
April  	April  	 NNP	O
2011 	2011 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
diagnosis  	diagnosis  	 NN	O
was  	was  	 VBD	O
invasive  	invasive  	 JJ	B-NP
urothelial  	urothelial  	 JJ	I-NP
carcinoma 	carcinoma 	 NN	I-NP
,  	,  	 ,	O
G3  	G3  	 NNP	O
with  	with  	 IN	O
a  	a  	 DT	O
component  	component  	 NN	O
of  	of  	 IN	O
bladder  	bladder  	 JJ	O
small  	small  	 JJ	O
cell  	cell  	 NN	B-NP
carcinoma 	carcinoma 	 NN	I-NP
,  	,  	 ,	O
T1  	T1  	 NNP	O
or  	or  	 CC	O
more 	more 	 JJR	O
.  	.  	 .	O
She  	She  	 PRP	O
was  	was  	 VBD	O
recommended  	recommended  	 VBN	O
to  	to  	 TO	O
visit  	visit  	 VB	O
our  	our  	 PRP$	O
hospital  	hospital  	 NN	O
for  	for  	 IN	O
combined  	combined  	 JJ	O
modality  	modality  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
of  	of  	 IN	O
bladder  	bladder  	 JJ	O
cancer 	cancer 	 NN	O
,  	,  	 ,	O
but  	but  	 CC	O
she  	she  	 PRP	O
refused  	refused  	 VBD	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
over  	over  	 IN	O
one  	one  	 CD	O
year 	year 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
May  	May  	 NNP	O
2012 	2012 	 CD	O
,  	,  	 ,	O
she  	she  	 PRP	O
came  	came  	 VBD	O
to  	to  	 TO	O
our  	our  	 PRP$	O
hospital  	hospital  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
chief  	chief  	 JJ	O
complaint  	complaint  	 NN	O
of  	of  	 IN	O
pain  	pain  	 NN	O
at  	at  	 IN	O
urination 	urination 	 NN	B-NP
.  	.  	 .	O
Cystoscopy  	Cystoscopy  	 NNP	B-NP
revealed  	revealed  	 VBD	I-NP
non-papillary  	non-papillary  	 JJ	I-NP
sessile  	sessile  	 JJ	O
tumor  	tumor  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
top  	top  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
bladder 	bladder 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
CT  	CT  	 NNP	B-NP
scan  	scan  	 VBD	O
demonstrated  	demonstrated  	 VBN	O
the  	the  	 DT	O
presence  	presence  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
right  	right  	 JJ	O
obturator  	obturator  	 JJ	B-NP
lymph  	lymph  	 NNS	I-NP
nodes  	nodes  	 VBP	I-NP
swollen  	swollen  	 VBN	O
up  	up  	 RP	O
to  	to  	 TO	O
1.2  	1.2  	 CD	O
cm  	cm  	 NN	O
in  	in  	 IN	O
size 	size 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
second  	second  	 JJ	O
TURBT  	TURBT  	 NNP	B-NP
was  	was  	 VBD	O
performed  	performed  	 VBN	O
and  	and  	 CC	O
the  	the  	 DT	O
diagnosis  	diagnosis  	 NN	O
was  	was  	 VBD	O
bladder  	bladder  	 JJ	O
small  	small  	 JJ	O
cell  	cell  	 NN	B-NP
carcinoma  	carcinoma  	 NNS	I-NP
( 	( 	 -LRB-	O
pT3N2M0 	pT3N2M0 	 NNP	O
)  	)  	 -RRB-	O
according  	according  	 VBG	O
to  	to  	 TO	O
urothelial  	urothelial  	 VB	O
cancer  	cancer  	 NN	B-NP
guidelines  	guidelines  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
Japanese  	Japanese  	 JJ	O
Urological  	Urological  	 NNP	O
Association  	Association  	 NNP	O
( 	( 	 -LRB-	O
JUA 	JUA 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Because  	Because  	 IN	O
she  	she  	 PRP	O
strongly  	strongly  	 RB	O
refused  	refused  	 VBD	B-NP
hospitalization  	hospitalization  	 VBN	I-NP
anymore 	anymore 	 RB	O
,  	,  	 ,	O
we  	we  	 PRP	O
started  	started  	 VBD	O
daily  	daily  	 JJ	O
oral  	oral  	 JJ	B-NP
intake  	intake  	 NN	I-NP
of  	of  	 IN	O
low  	low  	 JJ	O
dose  	dose  	 NN	B-NP
Tegafur-Uracil  	Tegafur-Uracil  	 NNS	I-NP
( 	( 	 -LRB-	O
100  	100  	 CD	O
mg 	mg 	 CD	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
After  	After  	 IN	O
one  	one  	 CD	O
month 	month 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
serum  	serum  	 JJ	B-NP
Neuron-Specific  	Neuron-Specific  	 JJ	I-NP
Enolase  	Enolase  	 NNP	I-NP
( 	( 	 -LRB-	O
NSE 	NSE 	 NNP	B-NP
;  	;  	 :	O
tumor  	tumor  	 NN	O
maker  	maker  	 NN	O
of  	of  	 IN	O
small  	small  	 JJ	O
cell  	cell  	 NN	O
cancer 	cancer 	 NN	O
)  	)  	 -RRB-	O
level  	level  	 NN	O
was  	was  	 VBD	O
elevated  	elevated  	 VBN	O
to  	to  	 TO	O
27.6  	27.6  	 CD	O
ng 	ng 	 CD	B-NP
/ 	/ 	 CD	I-NP
ml  	ml  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
right  	right  	 JJ	O
obturator  	obturator  	 JJ	B-NP
lymph  	lymph  	 NN	I-NP
node  	node  	 NNS	I-NP
was  	was  	 VBD	O
enlarged  	enlarged  	 VBN	O
up  	up  	 RP	O
to  	to  	 TO	O
1.9  	1.9  	 CD	O
cm 	cm 	 NNS	O
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
Trgafur-Uracil  	Trgafur-Uracil  	 JJ	B-NP
dose  	dose  	 NN	I-NP
was  	was  	 VBD	O
increased  	increased  	 VBN	O
to  	to  	 TO	O
200  	200  	 CD	O
mg  	mg  	 CD	B-NP
daily 	daily 	 JJ	O
.  	.  	 .	O
After  	After  	 IN	O
then 	then 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
serum  	serum  	 JJ	B-NP
NSE  	NSE  	 NNP	I-NP
level  	level  	 NN	I-NP
was  	was  	 VBD	O
decreased  	decreased  	 VBN	O
to  	to  	 TO	O
15.5  	15.5  	 CD	O
ng 	ng 	 CD	B-NP
/ 	/ 	 CD	I-NP
ml  	ml  	 NNS	I-NP
following  	following  	 VBG	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
size  	size  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
obturator  	obturator  	 JJ	B-NP
lymph  	lymph  	 JJ	I-NP
nodes  	nodes  	 NN	I-NP
with  	with  	 IN	O
partial  	partial  	 JJ	O
response  	response  	 NN	O
in  	in  	 IN	O
December  	December  	 NNP	O
2013 	2013 	 CD	O
.  	.  	 .	O
After  	After  	 IN	O
two  	two  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
follow-up  	follow-up  	 JJ	B-NP
period 	period 	 NN	I-NP
,  	,  	 ,	O
her  	her  	 PRP$	O
regular  	regular  	 JJ	B-NP
urine  	urine  	 JJ	I-NP
test  	test  	 NN	I-NP
showed  	showed  	 VBD	O
normal  	normal  	 JJ	B-NP
findings 	findings 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
no  	no  	 DT	O
apparent  	apparent  	 JJ	O
recurrence  	recurrence  	 NN	O
was  	was  	 VBD	O
detected  	detected  	 VBN	O
on  	on  	 IN	O
urinary  	urinary  	 JJ	B-NP
bladder  	bladder  	 NN	I-NP
with  	with  	 IN	O
MRI  	MRI  	 NNP	B-NP
and  	and  	 CC	O
Cystoscopy 	Cystoscopy 	 NNP	B-NP
.  	.  	 .	O
This  	This  	 DT	O
is  	is  	 VBZ	O
a  	a  	 DT	O
case  	case  	 NN	O
of  	of  	 IN	O
advanced  	advanced  	 JJ	O
bladder  	bladder  	 JJ	O
small  	small  	 JJ	O
cell  	cell  	 NN	O
carcinoma  	carcinoma  	 VBZ	O
significantly  	significantly  	 RB	O
improved  	improved  	 VBN	O
by  	by  	 IN	O
oral  	oral  	 JJ	B-NP
administration  	administration  	 NN	I-NP
of  	of  	 IN	I-NP
Tegafur-Uracil  	Tegafur-Uracil  	 JJ	I-NP
200  	200  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
day  	day  	 NN	I-NP
for  	for  	 IN	O
over  	over  	 IN	O
2  	2  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
